ASC 730-10 is the US GAAP standard that governs how companies account for research and development, and its central rule is simple: charge R&D costs to expense in the period they are incurred. There is no option to capitalize promising projects, no milestone that triggers deferral, and no management election to spread the cost against future revenue. The FASB chose this treatment because the link between R&D spending and future payoff is too speculative to measure reliably, and immediate expensing removes the discretion that would otherwise let managers shape earnings by deciding which projects to capitalize.
What Qualifies as Research and Development
The codification defines research as a planned search or critical investigation aimed at discovering new knowledge, with the hope that the knowledge will prove useful in developing or significantly improving a product or process. Development is the next step: translating research findings into a plan or design for a new or substantially improved product or process, including formulating concepts, designing and testing alternatives, building prototypes, and running pilot plants.
Activities that fall inside the definition include:
- Laboratory research aimed at discovering new knowledge
- Conceptual formulation and design of possible product or process alternatives
- Testing and evaluation of those alternatives
- Design, construction, and testing of preproduction prototypes and models
- Design and operation of a pilot plant that is not economically feasible for commercial production
- Engineering activity required to advance a product design to the point it meets functional and economic requirements and is ready for manufacture
Several activities that look similar sit outside the definition. Quality control during commercial production, troubleshooting breakdowns on the production line, routine or seasonal improvements to existing products, market research and market testing, and legal work tied to patent applications or litigation all fall outside R&D. So does the development of processes used strictly in selling or administrative functions, even when software is involved. Costs excluded from the R&D definition are not subject to the immediate expensing requirement; they may be capitalized, charged to cost of goods sold, or treated as period expenses depending on their nature, and misclassifying them in either direction is exactly the kind of error auditors look for.
Which Costs Must Be Expensed
Once an activity qualifies as R&D, several cost categories must be captured and charged to expense in the period they are incurred:
- Materials consumed, including chemicals, prototype components, and supplies used up during research
- Salaries, wages, and related benefits for employees directly engaged in R&D work
- Fees paid to consultants, contractors, and other third parties performing R&D on the company’s behalf
- A reasonable allocation of indirect costs such as rent and utilities for an R&D facility, charged in the same period as the direct costs they support
- The full cost of equipment or facilities acquired solely for a particular R&D project when the asset has no alternative future use
ASC 730-10-25-1 states the rule bluntly: all R&D costs shall be charged to expense when incurred.1FASB. Research and Development (Topic 730) A scientist’s salary hits the income statement in the month the work is performed. Materials consumed in a failed experiment are expensed in the quarter they were used. A company that spends $500,000 on qualifying R&D salaries and $150,000 on materials in a quarter reports the full $650,000 as R&D expense that quarter.
The decision is final. A cost recognized as R&D expense in one period cannot be retroactively capitalized if the project later succeeds and generates revenue. Timing follows the period in which the cost is incurred, not when a patent is filed, a prototype works, or a product launches.
The Alternative-Future-Use Exception
Not every asset used in R&D gets expensed on day one. Under ASC 730-10-25-2(a), materials, equipment, and facilities with an alternative future use are capitalized when acquired and depreciated normally; only the depreciation allocated to R&D periods flows through R&D expense.1FASB. Research and Development (Topic 730)
A general-purpose laboratory building, a computer server that will serve multiple departments, or testing equipment usable across several projects all pass the test. These assets go on the balance sheet and depreciate over their useful lives. A custom testing rig built for a single experimental compound, with no resale value and no use in any other project, fails the test and is written off entirely at purchase.
The determination happens at acquisition, not retroactively. If a company buys a machine believing it will serve only one project and later finds a second use for it, the cost has already been expensed. Judgment matters most here, and auditors push back when the classification looks inconsistent across similar assets.
R&D Performed Under Funding Arrangements
Many R&D dollars move between parties rather than staying inside one company, and the accounting depends on who bears the risk and who controls the results.
When a company hires a contractor to perform R&D on its behalf, the company expenses the payments as R&D costs in the periods the services are provided. Nonrefundable advance payments for future R&D services are deferred and recognized as R&D expense as the work is performed. If it becomes probable that the services will not be rendered, any remaining prepayment is expensed immediately.
The contractor performing the work does not report R&D expense. It treats the costs as cost of revenue and the payments received as service revenue, because the economic risk of the R&D outcome sits with the funding party.
ASC 730-20 covers more complex arrangements where an entity receives funding from others to conduct R&D while potentially retaining rights to the results. The question is whether a genuine transfer of financial risk has occurred. If repayment depends solely on whether the R&D produces future economic benefits, the arrangement is treated as a contract to perform R&D services, and the funding is recognized as revenue. If the entity has an obligation to repay regardless of outcome, the funding is treated as a liability.
Required Financial Statement Disclosures
ASC 730-10-50-1 requires companies to disclose the total R&D costs charged to expense in each period for which an income statement is presented, including R&D costs incurred for computer software to be sold, leased, or otherwise marketed.2Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive
The disclosure usually sits in the notes, though some companies present R&D as a separate line item on the income statement. The notes should also describe the company’s accounting policy for R&D costs, particularly the criteria used to decide whether equipment and facilities have alternative future uses.
SEC staff review R&D disclosures closely in industries where R&D spending is material, such as pharmaceuticals and technology. Recurring areas of inquiry include whether R&D costs should be disaggregated by major product or project category, how the company determines when to stop tracking costs by individual project, and whether the disclosed allocation methodology is consistent with how management actually makes resource decisions internally.
What ASC 730-10 Does Not Cover
Several costs that feel like R&D are governed by other guidance, and applying ASC 730-10 to them produces the wrong answer.
Internal-use software. Software developed for a company’s own use follows ASC 350-40, not ASC 730-10. Under the current three-stage model, preliminary project costs are expensed, application development costs are capitalized once management commits to funding and completion is probable, and post-implementation costs are expensed. ASU 2025-06 removes the stage references and reframes the capitalization triggers; it takes effect for annual reporting periods beginning after December 15, 2027, with early adoption permitted.3FASB. FASB Issues Standard That Makes Targeted Improvements to Internal-Use Software Guidance
Acquired in-process R&D. When a company acquires another business under ASC 805, incomplete R&D projects at the target are capitalized at fair value as a separate indefinite-lived intangible, tested for impairment at least annually, and reclassified and amortized once the project is completed. The reasoning is that the acquirer paid real consideration for those projects and the purchase price already reflects their risk-adjusted value.
Contract R&D performed for others. R&D performed under contract for another party is outside ASC 730-10 and follows general contract accounting; the performer records cost of revenue and service revenue rather than R&D expense.
Extractive industry activities. Prospecting, exploration, and drilling unique to extractive industries are excluded, though those companies still follow ASC 730-10 for research comparable to that of other entities, such as developing improved extraction techniques.
Tax treatment. ASC 730-10 governs the books, not the tax return. IRC Section 174 has required capitalization and amortization of specified research and experimental expenditures since 2022, and the One Big Beautiful Bill Act enacted new Section 174A to restore immediate deductibility for domestic R&D for tax years beginning after December 31, 2024, while foreign R&D remains on a fifteen-year amortization schedule. Book-tax differences that arose during the capitalization years, and the ongoing difference for foreign R&D, still need to be tracked separately from the GAAP treatment.
IFRS reporters. Companies filing under IFRS apply IAS 38, which requires capitalization of development costs once six specific criteria are met. Two companies working on the same project can therefore report very different assets and earnings depending on which framework governs. Multinational groups preparing dual reports have to track development costs under both standards in parallel.